908 results on '"Åsberg, Anders"'
Search Results
102. Short‐ and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity
103. Multiplexed measurement of binding- and neutralizing antibodies to SARS-CoV-2 variants in 12.000 post-vaccine sera
104. A Comorbidity Index and Pretransplant Physical Status Predict Survival in Older Kidney Transplant Recipients: A National Prospective Study
105. High Plasma Oxalate Levels Early After Kidney Transplantation Are Associated With Impaired Long-Term Outcomes
106. Drug Disposition Protein Quantification in Matched Human Jejunum and Liver From Donors With Obesity
107. Virologic Suppression Measured by a Cytomegalovirus (CMV) DNA Test Calibrated to the World Health Organization International Standard Is Predictive of CMV Disease Resolution in Transplant Recipients
108. A snapshot of European registries on chronic kidney disease patients not on kidney replacement therapy
109. The ERA Registry Annual Report 2019: summary and age comparisons
110. Mycophenolate Acid and Balancing the Risk for Male Allograft Recipients
111. Use of Statins in Kidney Transplant Recipients in Norway
112. Estimert glomerulær filtrasjonshastighet som mål på nyrefunksjon
113. A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients
114. The ERA Registry Annual Report 2019: summary and age comparisons
115. Endothelial Dysfunction and 6-Year Risk of Mortality in Kidney Transplant Recipients
116. Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response
117. Impact of Genetic Polymorphisms in Cytomegalovirus Glycoprotein B on Outcomes in Solid-Organ Transplant Recipients with Cytomegalovirus Disease
118. Deciphering transplant outcomes of expanded kidney allografts donated after controlled circulatory death in the current transplant era. A call for caution
119. Elevated Terminal C5b-9 Complement Complex 10 Weeks Post Kidney Transplantation Was Associated With Reduced Long-Term Patient and Kidney Graft Survival
120. A snapshot of European registries on chronic kidney disease patients not on kidney replacement therapy
121. Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial
122. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
123. Chronic musculoskeletal complaints as a predictor of mortality—The HUNT study
124. Importance of hematocrit for a tacrolimus target concentration strategy
125. Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria
126. UGT1A1*28 is Associated with Decreased Systemic Exposure of Atorvastatin Lactone
127. Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation
128. Accelerated 18O-labeling in urinary proteomics
129. Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout ( Oncorhynchus mykiss) hepatocytes
130. Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial
131. Low Immunization Rate in Kidney Transplant Recipients Also After Dose 2 of the BNT162b2 Vaccine: Continue to Keep Your Guard up!
132. Increased systemic exposure of once‐daily tacrolimus in renal transplant recipients on marine omega‐3 fatty acid supplementation
133. Insulin secretion and action after pancreas transplantation. A retrospective single-center study
134. FC 086GLOMERULI PROTEOME ANALYSIS REVEALS EARLY DIFFERENCES BETWEEN PRE-EXISTING AND DE-NOVO TYPE 2 DIABETES IN HUMAN RENAL ALLOGRAFTS
135. Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats
136. Estimert glomerulær filtrasjonshastighet som mål på nyrefunksjon
137. A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients.
138. Uric acid and clinical correlates of endothelial function in kidney transplant recipients
139. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
140. Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin
141. Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients
142. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
143. Blood Pressure Treatment in Kidney Transplant Recipients—Can We Improve?
144. Patient selection for islet or solid organ pancreas transplantation: experiences from a multidisciplinary outpatient-clinic approach
145. Atorvastatin Metabolite Measurements as a Diagnostic Tool for Statin-Induced Myopathy
146. Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone Metabolite
147. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation
148. A Population Pharmacokinetic Model of Ciclosporin Applicable for Assisting Dose Management of Kidney Transplant Recipients
149. Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response.
150. ERA Registry Annual Report 2019: summary and age comparisons.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.